Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target

Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ: PRAX) and maintained a price target of $582. This endorsement reflects confidence in the company's potential for growth.